Irritable Bowel Syndrome Trial, Recruiting NCT02421705 Sponsor: KU Leuven Condition: Irritable Bowel Syndrome
Back to Irritable Bowel Syndrome

Irritable Bowel Syndrome Trial, Recruiting

NCT02421705
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Irritable Bowel Syndrome (IBS) based on a standard set of medical criteria (called ROME III), with no other clear medical reason found for their symptoms (Group 1)
  • People who have been diagnosed with active ulcerative colitis, confirmed by at least one internal bowel examination (Group 2)
  • People who have ulcerative colitis that is currently in remission (not actively flaring), confirmed by at least one internal bowel examination — either with or without IBS symptoms (Group 3)
  • Healthy volunteers who have no stomach or abdominal pain or complaints (Group 4)
  • People who have been diagnosed with active Crohn's disease, confirmed by at least one internal bowel examination (Group 5)
  • People who have Crohn's disease that is currently in remission (not actively flaring), confirmed by at least one internal bowel examination — either with or without IBS symptoms (Group 6)
  • Participants in all groups must be willing to stop any medications that affect gut movement or sensation for at least 24 hours before the study

Who may not be able to join:

  • People who have serious kidney disease, liver disease, thyroid problems, or problems with blood clotting
  • People who have had abdominal surgery, unless it was a straightforward, uncomplicated appendix removal

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Guy Boeckxstaens, MD, Catholic University Leuven and Universitary Hospitals Leuven

Phone: 0032-16-341943

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
KU Leuven
Registry
ClinicalTrials.gov
Start date
1 February 2010
Est. completion
1 January 2099

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

differences in visceral sensitivity in different study groups (Visceral sensitivity will me measured by performing a rectal barostat test)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov